Same molecule, same injection, same side effects. Different indication, different dose, different insurance coverage. That is basically the whole story.
🔑 Key Takeaways
- Wegovy and Ozempic contain the exact same active ingredient (semaglutide) from the same manufacturer (Novo Nordisk). The difference is indication, dose, and pen design
- Wegovy is FDA-approved for chronic weight management in adults with BMI 30+, or 27+ with comorbidity, and adolescents 12+ with obesity. It is also approved for cardiovascular risk reduction in obesity and for MASH (liver disease)
- Ozempic is FDA-approved for type 2 diabetes, cardiovascular risk reduction in T2D with heart disease, and kidney disease protection in T2D with chronic kidney disease. Weight loss is a side effect, not an indication
- Wegovy reaches a higher maximum dose (2.4 mg weekly) compared to Ozempic (2.0 mg weekly), which produces more weight loss
- Ozempic uses multi-dose pens with 4 to 8 doses per pen. Wegovy uses single-dose pens with one dose per pen
- Side effect profiles are essentially identical (nausea, diarrhea, constipation, vomiting, thyroid boxed warning). Rates are slightly higher on Wegovy because the dose is higher
- Insurance usually covers Ozempic easily with a T2D diagnosis. Wegovy coverage requires obesity-specific prior authorization and is harder to get approved
- Off-label Ozempic for weight loss is common, but is less effective than Wegovy because of the lower max dose
This page answers every common question about the Wegovy vs Ozempic decision: the FDA approvals that differentiate them, why the maximum doses differ, what the trials actually showed, side effect and cost comparison, insurance realities, who should pick which, and whether you can switch between them.
What's the Difference Between Wegovy and Ozempic?
Same molecule. Different target patient.
Both contain semaglutide, a GLP-1 receptor agonist from Novo Nordisk. The chemistry is identical. What differs is what the FDA approved each brand for, the dose range, and the pen design. Wegovy was designed for weight management and reaches a higher therapeutic dose. Ozempic was designed for type 2 diabetes and tops out at a slightly lower dose. Neither is interchangeable with the other, even though they work through exactly the same mechanism in the body.
Wegovy vs Ozempic: Specs Side-by-Side
| Wegovy | Ozempic | |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Manufacturer | Novo Nordisk | Novo Nordisk |
| FDA indication | Chronic weight management, CV risk reduction in obesity, MASH | Type 2 diabetes, CV risk reduction in T2D, kidney disease protection in T2D |
| Approved ages | Adults, adolescents 12+ | Adults (not approved for adolescents) |
| Max weekly dose | 2.4 mg | 2.0 mg |
| Starting dose | 0.25 mg weekly | 0.25 mg weekly |
| Pen design | Single-dose pen (one per injection) | Multi-dose pen (4 to 8 doses per pen) |
| Injection frequency | Once weekly | Once weekly |
| Avg weight loss | ~14.9% (STEP 1 at 68 weeks) | ~5-10% (off-label, at lower max dose) |
| List price / month | ~$1,350 | ~$900 |
| Cash program | NovoCare $199 (months 1-2), $349 after | No dedicated cash program (insurance-based) |
FDA-Approved Uses: Where They Differ
The single biggest practical difference.
Wegovy approvals
- Chronic weight management: Adults with BMI 30+, or 27+ with a weight-related condition (type 2 diabetes, hypertension, high cholesterol, sleep apnea)
- Pediatric obesity: Adolescents age 12+ with BMI in the 95th percentile or higher
- Cardiovascular risk reduction: Adults with obesity and established cardiovascular disease, based on the SELECT trial (20% reduction in major CV events)
- MASH (metabolic dysfunction-associated steatohepatitis): Added indication for adults with moderate to advanced liver fibrosis
Ozempic approvals
- Type 2 diabetes: Primary indication, as an adjunct to diet and exercise for glycemic control
- Cardiovascular risk reduction in T2D: For adults with T2D and established cardiovascular disease
- Kidney disease protection: For adults with T2D and chronic kidney disease
Ozempic is widely prescribed off-label for weight loss in people who do not have T2D. This is legal but produces less weight loss than Wegovy because the max dose is lower, and insurance often denies the prescription without a T2D diagnosis.
Wegovy vs Ozempic for Weight Loss
Both work. Wegovy works more.
The STEP 1 trial (NEJM 2021) established Wegovy's weight loss efficacy: 14.9% average body weight reduction at 68 weeks on 2.4 mg weekly, with 86% of participants achieving at least 5% weight loss and 50% achieving 15% or more.
Ozempic at its max 2.0 mg weekly dose produces roughly 5 to 10% average weight loss in off-label weight-management use. At the diabetes doses (0.5 to 1.0 mg), weight loss is smaller. The dose ceiling is the main reason Wegovy outperforms Ozempic for weight management.
No large head-to-head trial has directly compared Wegovy vs Ozempic at each drug's maximum dose specifically for weight loss. The comparison rests on cross-trial data and the shared pharmacology: same molecule, higher dose produces proportionally more effect.
What the STEP and SUSTAIN Trials Actually Showed
Numbers patients miss when they read the marketing.
The Wegovy weight loss number you see everywhere, "about 15 percent average body weight loss," comes from STEP 1, not the whole STEP program. The full picture across STEP 1 through STEP 8 is more useful, because it shows what happens in different populations and what happens after you stop.
| Trial | Population | Duration | Avg weight loss on Wegovy 2.4 mg |
|---|---|---|---|
| STEP 1 | Adults with obesity, no diabetes | 68 weeks | 14.9% |
| STEP 2 | Adults with obesity AND type 2 diabetes | 68 weeks | 9.6% |
| STEP 3 | Obesity + intensive behavioral therapy | 68 weeks | 16.0% |
| STEP 4 | 20-week run-in, then continue vs switch to placebo | 68 weeks total | 17.4% (continued) vs +6.9% regain after switching to placebo |
| STEP 5 | Obesity, 2-year extension | 104 weeks | 15.2% |
| STEP TEENS | Adolescents 12 to 17 with obesity | 68 weeks | 16.1% |
| SELECT | Overweight/obese adults with established CV disease, no diabetes | 3+ years | 9.4%, plus 20% reduction in major CV events |
The Ozempic side runs through the SUSTAIN program. SUSTAIN 1 through 7 looked at glycemic control as the primary endpoint, with weight as secondary. SUSTAIN-FORTE later established the 2.0 mg weekly dose for additional A1c reduction.
| Trial | Population | Dose | A1c reduction / weight loss |
|---|---|---|---|
| SUSTAIN 1 | Drug-naive T2D | 0.5 / 1.0 mg | 1.45% / 1.55% A1c reduction; 3.7 / 4.5 kg weight loss |
| SUSTAIN 6 | T2D with high CV risk | 0.5 / 1.0 mg | 26% reduction in major CV events |
| SUSTAIN-FORTE | T2D inadequately controlled on metformin | 2.0 mg vs 1.0 mg | Additional 0.23% A1c drop and 0.74 kg additional weight loss at 2.0 mg |
| FLOW | T2D with chronic kidney disease | 1.0 mg | 24% reduction in major kidney disease events (basis for the 2024 kidney indication) |
Two takeaways most articles skip. First, weight loss in obese diabetics on Wegovy is meaningfully smaller (9.6% in STEP 2) than in obese non-diabetics (14.9% in STEP 1). The molecule does not work as hard when the metabolic environment is already deranged. Second, STEP 4 is the regain trial. Patients on Wegovy 2.4 mg who switched to placebo at week 20 regained two thirds of what they lost over the next 48 weeks. The drug works while you take it, and stops working when you stop.
Weight Regain After Stopping Wegovy or Ozempic
The honest answer most patients are not told upfront.
STEP 4 is the cleanest data on what happens when you stop. After 20 weeks of titration to 2.4 mg, patients who continued on Wegovy lost an additional 7.9% of body weight over the next 48 weeks. Patients who switched to placebo at week 20 gained back 6.9% over the same period. Net difference at week 68: 17.4% loss vs 5% loss. Same drug, same starting point, just whether you kept taking it.
The biology behind this is straightforward. GLP-1 agonists lower the body's defended weight setpoint while you take them. They do not reset it permanently. Stop the drug and appetite signaling, gastric emptying, and reward-driven eating return to baseline within a few weeks. Most patients regain at a slower rate than their prior weight gain trajectory but the curve goes the wrong way once the drug clears.
This applies equally to Ozempic. The semaglutide molecule is the same; the underlying pharmacology is the same. Patients on off-label Ozempic who lose 8% over a year typically regain 4 to 5% within 6 to 12 months of stopping unless they switch to a different agent or implement intensive lifestyle support.
Practical implication: both drugs are best understood as long-term medications, not 6-month interventions. If long-term continuation is not realistic for your insurance, budget, or tolerance, build a maintenance plan with your prescriber before titrating up. Tapering down to a lower maintenance dose, switching to an oral GLP-1, or transitioning to a tirzepatide regimen are all options that produce less rebound than abrupt discontinuation.
Dosing and Titration
Both drugs titrate slowly from the same starting dose to reduce GI side effects.
Wegovy Titration (for weight management)
- Weeks 1-4: 0.25 mg weekly
- Weeks 5-8: 0.5 mg weekly
- Weeks 9-12: 1.0 mg weekly
- Weeks 13-16: 1.7 mg weekly
- Week 17 onward: 2.4 mg weekly (target maintenance dose)
Ozempic Titration (for type 2 diabetes)
- Weeks 1-4: 0.25 mg weekly (starting, not yet therapeutic)
- Weeks 5-8: 0.5 mg weekly
- If needed: Increase to 1.0 mg weekly
- Max: 2.0 mg weekly (added in 2022 for additional glycemic control)
Holding a dose level for an extra 4 weeks when GI symptoms are strong is acceptable for both drugs. Every step-up triggers a new wave of nausea for many patients, which usually fades within 2 to 4 weeks at the new dose.
Wegovy vs Ozempic Side Effects
Same profile, slightly different rates.
Because Wegovy is dosed higher, side effects are more common on Wegovy than on Ozempic. The side effect categories are identical.
| Side effect | Wegovy 2.4 mg | Ozempic 1.0 mg |
|---|---|---|
| Nausea | ~44% | ~20% |
| Diarrhea | ~30% | ~12% |
| Vomiting | ~24% | ~9% |
| Constipation | ~24% | ~5% |
| Headache | ~14% | ~7% |
| Fatigue | ~11% | ~4% |
Both carry the identical boxed warning for medullary thyroid carcinoma and MEN2 family history. Both carry the same rare-but-serious risks: pancreatitis, gallbladder disease, kidney injury, hypersensitivity reactions, and diabetic retinopathy worsening in patients with pre-existing retinopathy.
Cost: Wegovy vs Ozempic
| Option | Wegovy | Ozempic |
|---|---|---|
| List price (cash) | ~$1,350/month | ~$900/month |
| Manufacturer cash program | NovoCare: $199 months 1-2, $349 after | No dedicated cash program |
| Commercial insurance | $25-$250 copay (with PA) | $25-$200 copay (usually easier to get approved) |
| Medicare | Covered under GLP-1 Bridge Program starting July 1, 2026 (~$50/month) | Covered for T2D only |
| Medicaid | Varies by state | Usually covered for T2D |
NovoCare is the most meaningful 2026 cost change. For uninsured or underinsured patients, $199/month for the first 2 months and $349/month after is significantly better than the $1,350 list price. See our GLP-1 without insurance page for the full options.
Insurance Reality
The practical difference patients actually feel.
Ozempic is usually approved by commercial insurance with a type 2 diabetes diagnosis, a standard prior authorization, and minimal friction. Medicare Part D covers it for T2D. Medicaid covers it in most states for T2D.
Both rank near the top of the 2026 weight loss injections leaderboard, but the prescription pathway is different. Wegovy is harder. Commercial insurers require obesity-specific prior authorization, usually with documented BMI, at least one comorbidity, evidence of prior lifestyle intervention attempts, and sometimes a failed trial of a lower-cost weight-loss option first. Medicare historically did not cover weight-loss drugs at all, but the GLP-1 Bridge Program starting July 2026 adds Wegovy coverage for eligible beneficiaries.
This is why many patients start on Ozempic (covered) for weight loss rather than Wegovy (the approved weight-loss version). The tradeoff is meaningful: Ozempic at its max dose typically produces 5 to 10% weight loss, while Wegovy at 2.4 mg produces closer to 15%.
Compounded Semaglutide in 2026: What Changed After the Shortage Ended
The most consequential 2026 change in this space.
From late 2022 through early 2025, both Ozempic and Wegovy sat on the FDA shortage list. That triggered a federal exemption (section 503A and 503B of the FDCA) that allowed compounding pharmacies to legally produce semaglutide at scale. Telehealth platforms like Hims, Henry Meds, Mochi, and dozens of smaller clinics built six-figure monthly pipelines on $200 to $400 cash semaglutide.
The FDA officially declared the semaglutide shortage resolved in February 2025. The legal protection that allowed mass compounding ended at that point. The 2026 reality:
- Mass compounding by 503B outsourcing facilities is no longer permitted. Large compounders that produced FDA-listed-shortage semaglutide had to stop bulk production. The big online pharmacies that fueled the 2024 telehealth boom either pivoted to other GLP-1 molecules or shut down their semaglutide programs.
- 503A patient-specific compounding is still legal, but only for individualized prescriptions where the prescriber documents a clinical reason the FDA-approved product does not work for that specific patient (allergy to a fixed-pen excipient, dose increment not commercially available, etc). This is a narrow lane, not a price-arbitrage lane.
- Most "compounded semaglutide" sold online in 2026 is operating in a gray zone. Some pharmacies are using technical workarounds (B12 mixtures, custom dose strengths). Novo Nordisk has filed multiple lawsuits, and several state pharmacy boards have issued cease-and-desist orders.
- NovoCare is Novo Nordisk's response. Recognizing that the cash compounded market exposed real demand from uninsured patients, Novo launched NovoCare Pharmacy in 2025 with $199/month for the first 2 months and $349/month after for self-pay Wegovy. This puts on-label semaglutide within reach of patients who used to pay $250 to $400 to compounders.
If you are considering compounded semaglutide in 2026
- Verify the pharmacy is licensed in your state and operates under 503A patient-specific compounding rules
- Ask whether the active ingredient is sourced from an FDA-registered API supplier with a Drug Master File on record
- Compare total cost to NovoCare ($199/$349). For most patients, on-label Wegovy via NovoCare is now cheaper than reputable 503A compounding
- Avoid any product labeled "semaglutide for research use," "not for human consumption," or sold without a prescription. These are not pharmacy products and have no quality oversight
- Confirm with your prescriber that they will continue your titration on the FDA-approved product if you choose to switch off compounded
Drug Interactions and Special Populations
The clinical context that changes who can take either drug safely.
Drug interactions to flag with your prescriber
- Insulin and sulfonylureas (glipizide, glimepiride): Both Wegovy and Ozempic increase the risk of hypoglycemia when combined with insulin or sulfonylureas. Most prescribers reduce the insulin or sulfonylurea dose by 20 to 30% when starting semaglutide
- Oral medications generally: Semaglutide slows gastric emptying, which can reduce absorption of oral drugs taken close to the injection. Levothyroxine, oral contraceptives, warfarin, and oral antibiotics are the most commonly affected. Take oral meds 30 to 60 minutes before any food when possible
- Other GLP-1 or GLP-1/GIP agonists: Do not combine with tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), or dulaglutide (Trulicity). Stacking GLP-1s increases GI side effects without proven added benefit
- Insulin secretagogues (repaglinide, nateglinide): Also increase hypoglycemia risk; dose reduction usually required
Pregnancy and breastfeeding
Neither Wegovy nor Ozempic is approved during pregnancy. Animal studies have shown harm at therapeutic doses. The FDA recommends discontinuing semaglutide at least 2 months before a planned pregnancy, since the drug has a long half-life (about 1 week) and steady-state takes 4 to 5 weeks to clear. If you become pregnant unexpectedly while on semaglutide, contact your prescriber immediately, do not panic, and stop the drug. Outcomes data from accidental pregnancy exposures has not shown a strong human teratogenic signal so far, but the formal recommendation is unchanged.
Breastfeeding data is limited. Semaglutide is a large peptide and is unlikely to cross into breast milk in clinically meaningful quantities, but the manufacturer recommends weighing risks vs benefits with your prescriber.
Adolescents 12 to 17
Wegovy is approved down to age 12 for adolescents with obesity (BMI at or above the 95th percentile for age and sex). Ozempic has no pediatric approval. The STEP TEENS trial showed 16.1% average weight loss in adolescents at 68 weeks, slightly better than the adult STEP 1 result. Adolescents tolerate semaglutide similarly to adults, with the same GI side effect profile. Bone density, growth, and puberty markers were not adversely affected in the trial.
Older adults (65+)
No dose adjustment is needed for age alone. Older adults respond similarly to younger adults but tend to be more sensitive to dehydration from GI side effects, more likely to be on insulin or sulfonylureas (hypoglycemia risk), and more likely to have moderate kidney impairment (which can amplify nausea). Slower titration and closer monitoring are common in this population.
Kidney and liver impairment
Semaglutide is not significantly cleared by the kidneys, so it can be used in chronic kidney disease, including dialysis patients, with no dose adjustment. Severe acute kidney injury has been reported, almost always secondary to dehydration from vomiting and diarrhea, which reverses with hydration and dose reduction. Mild to moderate hepatic impairment requires no adjustment; severe hepatic impairment data is limited.
Alcohol
No formal contraindication, but semaglutide changes how alcohol is tolerated. Many patients report sharply reduced alcohol cravings on therapy (a real, well-documented effect being studied formally now). Drinking on a full stomach is harder because gastric emptying is delayed, so alcohol absorption is slower and peaks later than expected. Heavy drinking on semaglutide also increases pancreatitis risk.
Who Should Pick Wegovy vs Ozempic
Pick Wegovy if
- You have obesity (BMI 30+) or overweight (27+) with a weight-related condition, and your primary goal is weight loss
- You have cardiovascular disease plus obesity, even without T2D (SELECT trial indication)
- You have MASH / NAFLD with moderate to advanced fibrosis
- You are an adolescent age 12+ with obesity (Wegovy has pediatric approval, Ozempic does not)
- You want the maximum weight-loss effect within the semaglutide family
- You can get insurance coverage or afford the NovoCare cash program
Pick Ozempic if
- You have type 2 diabetes (the primary FDA indication)
- You have T2D plus established cardiovascular disease (Ozempic's CV indication)
- You have T2D plus chronic kidney disease (Ozempic's unique kidney protection indication)
- Your insurance covers Ozempic but not Wegovy, and some weight loss is still a reasonable secondary goal
- You want multi-dose pen convenience over single-dose pens
Can You Switch Between Wegovy and Ozempic?
Yes, and it's common.
Because they are the same molecule, switching is straightforward. Physicians typically match the new-drug dose to the old-drug dose when transitioning. If you were on Ozempic 1.0 mg weekly, your prescriber would usually start Wegovy at 1.0 mg or 1.7 mg (Wegovy does not have a 1.0 mg dose, so the next step is 1.7 mg). Allow 1 week between the last dose of the old drug and the first dose of the new one.
The reasons to switch vary. Most common: starting on Ozempic (easier insurance approval) and switching to Wegovy once the T2D diagnosis is on file or once weight-loss goals push past what Ozempic alone can deliver. Less common: switching from Wegovy to Ozempic due to side effects at the 2.4 mg dose. Both directions are clinically valid.